Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Eli Lilly

Eli Lilly To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Benzinga

Long-Term Study Shows Sustained Remission With Eli Lilly's Ulcerative Colitis Drug

Eli Lilly and Co. (NYSE:LLY) unveiled new data on Tuesday from LUCENT-3, the single-arm long-term Phase 3 open-label extension of LUCENT-1 and LUCENT-2, which evaluated the efficacy and safety of mirikizumab in patients with ulcerative colitis for an additional three years of treatment (up to four years total).

Benzinga

Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal

Eli Lilly just got great news, courtesy of Pfizer and Trump, leading shares to their highest level in five months. Its rally may just be getting started.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Eli Lilly Eyes India For Manufacturing, Plans To Spend $1 Billion

Eli Lilly and Co. (NASDAQ:LLY) plans to invest over $1 billion in India to strengthen its manufacturing network, according to Reuters.

Benzinga

Trump’s Drug Price Cuts: Boom or Bust for These 3 Pharma Giants

Trump’s drug price plan drove a Pfizer rally, leaves Eli Lilly buffered by U.S. investments, and could boost JNJ if it secures similar tariff relief.

MarketBeat

Eli Lilly Shares Are Trading Higher Wednesday: What's Going On?

Eli Lilly And Company (NYSE:LLY) shares are trading higher Wednesday after President Donald Trump recently announced a deal with Pfizer as well as the ‘TrumpRx’ site to decrease prices.

Benzinga

Pfizer's TrumpRx Pact Sends Shockwaves: Why UnitedHealth, Lilly And CVS Can't Look Away

Pfizer Inc's (NYSE:PFE) deal with Washington isn't just a handshake in the Oval Office — it's a seismic jolt to America's drug-pricing game. By agreeing to sell medicines on the government's new TrumpRx platform at steep discounts and extend "most favored nation" (MFN) pricing to Medicaid, Pfizer bought itself a…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Stocks Settle Higher as Drug Makers and Chip Stocks Rally

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed up +0.41%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.18%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.28%. December E-mini S&P futures (ESZ25 ) rose +0.39%, and December E-mini Nasdaq futures...

Barchart

Big Pharma’s retreat: Is NHS pricing behind investor pullbacks?

Multinational pharmaceutical firms are pulling pack or pausing investments in the UK, blaming a lack of competitive drug pricing.

Euronews

Weight Loss Wars: Is Novo Nordisk’s Dominance Safe Against Eli Lilly?

As the battle for dominance heats up in the weight loss market, which stock is a better investment now?

Barchart

Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk

The U.S. pharmaceutical industry is at the center of a policy maelstrom. President Donald Trump on Sep 25, put a 100% tariff on imported branded and patented medicines starting from Oct 1 with threats that tariffs might go up to as much as 250% in future. The instant market impact…

Benzinga

What is lecanemab, the newly approved Alzheimer’s drug? Can it really slow down dementia?

Dementia is a condition that results in progressive memory or thinking problems. It’s now the most common cause of death in Australia. There are many different causes of dementia, but Alzheimer’s disease accounts for around 60–80% of all cases.

The Conversation

NHS facing ‘critical threat’ after Trump pressure to hike drug prices

NEWS ANALYSIS: Drug prices in the UK could rise amid 100 per cent tariffs on branded medicines and pressure from US President Donald Trump to stop ‘global freeloading’, Alicja Hagopian reports

The Independent UK

FDA Approves Eli Lilly's Drug For Advanced Breast Cancer

On Thursday, the U.S. Food and Drug Administration (FDA) approved Eli Lilly and Co.’s (NYSE: LLY) Inluriyo (imlunestrant) for adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–), ESR1-mutated advanced or metastatic breast cancer (MBC) whose disease progressed after at least one line of endocrine therapy (ET).

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Eli Lilly Stock Is Trading Down Thursday: What's Behind The Move?

Eli Lilly and Company (NYSE: LLY) shares are trading lower after the company ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began. The termination is a setback for Lilly’s obesity pipeline among growing investor expectations.

Benzinga

Eli Lilly Ends Bimagrumab Obesity Study Weeks After Launch

On Wednesday, Eli Lilly Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began.

The Guardian - UK

Moderna boss defends UK in drug-pricing row as he opens £150m Oxfordshire facility

‘We’re here to invest,’ says Darius Hughes as he calls comments by other pharma companies ‘a little harsh’

Benzinga

United Kingdom The Worst European Country For Drug Prices: Eli Lilly CEO

Eli Lilly and Co. (NYSE:LLY) CEO Dave Ricks strongly criticized the United Kingdom's approach to drug pricing, describing it as "probably the worst country in Europe" for pharmaceutical prices.

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Business news live: Another pharma firm criticises UK, Spanish energy company to invest €20bn in Britain

Stock market news plus latest business and personal finance updates from Wednesday

The Guardian - UK

UK is ‘worst country in Europe’ for drug prices, says Mounjaro maker

Eli Lilly CEO says Britain’s strict regime means it could miss out on new drugs being rolled out unless it pays more

The Guardian - UK

Eli Lilly calls UK ‘worst country in Europe’ for drug prices; gold nears record high - as it happened

Spot gold trading just below Monday’s fresh record high

The Independent UK

Wegovy in pill form could soon be a reality as tests show it is just as effective as shots

It’s unclear how much such a pill would cost, but Novo Nordisk’s Ozempic and Wegovy shots currently go for several hundred dollars each month out of pocket

Benzinga

Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs

The U.S. Food and Drug Administration’s recent enforcement action against drug promotion is sending ETFs with exposure to weight-loss treatment manufacturers into question.

Benzinga

Novo Nordisk's Wegovy Outperforms Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death: Study

Novo Nordisk A/S (NYSE:NVO) presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025.

The Guardian - UK

Novo Nordisk shares climb after positive anti-obesity pill results

Danish drugmaker jumps by about £9bn as trial shows ‘significant weight loss’ with tablet version of Wegovy

1 … 6 7 8 9

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.